Storys zum Thema Health

15.04.2015 – 08:02
Daiichi Sankyo Europe GmbH
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in ...
mehr
14.04.2015 – 09:03
Novo Nordisk
Novo Nordisk Extends Programme for Children With Diabetes in Developing Countries
Bagsværd, Denmark (ots/PRNewswire) - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes(R) in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 ...
mehr
13.04.2015 – 15:31
CGI Group Inc.
Alberta Health Extends Application Maintenance Services Contract With CGI
Edmonton, Alberta (ots/PRNewswire) - Stock Market Symbols GIB.A (TSX) GIB (NYSE) http://www.cgi.com/newsroom CGI is pleased to announce the renewal of its application maintenance services (AMS) contract with the Ministry of Health in Alberta (Alberta Health) for three years. The original contract was signed in 2011 for three and a half years, and the high quality work ...
mehr
07.04.2015 – 14:02
Merck and Pfizer
Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) - In the United States and Canada, XALKORI will be co-promoted by EMD ...
mehr
07.04.2015 – 13:31
Resverlogix Corp.
Resverlogix Receives Two Patents for RVX-208 in China
Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing ...
mehr
07.04.2015 – 08:01
Shire Pharmaceuticals Group Plc
Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD
Lexington, Massachusetts (ots/PRNewswire) - - Potential Launch of SHP465 Anticipated in Second Half of 2017 - Exclusivity for Shire's Overall ADHD Product Portfolio Extends to 2029 Shire plc today announces that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a clear regulatory path ...
mehr

06.04.2015 – 14:01
Shire Pharmaceuticals Group Plc
Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
Lexington, Massachusetts (ots/PRNewswire) - Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA origin]). The patents listed in the FDA Orange Book for LIALDA and GATTEX protect the innovation and value Shire brings to patients who benefit from these important medicines. ...
mehr
01.04.2015 – 22:18
Pivotal Therapeutics Inc
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the United Stated Patent and Trademark Office (USPTO) has ...
mehr
31.03.2015 – 14:02
Takeda Pharmaceuticals Europe Ltd
New Post-hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia
Vienna (ots/PRNewswire) - FOR MEDICAL MEDIA Takeda Pharmaceuticals International GmbH ("Takeda") and Sunovion Pharmaceuticals Inc. ("Sunovion") today announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda(R) (lurasidone) in patients with schizophrenia at the 23rd European ...
mehr
31.03.2015 – 07:31
Galderma
World's Leading Rosacea Experts Join Forces for First Global Rosacea Awareness Month to Help Drive Awareness and Extend Support for the 40 Million People Affected by Rosacea
Lausanne, Switzerland (ots/PRNewswire) - For non-US media - Global Rosacea Tweetathon set to bring the realities of living with rosacea under the spotlight #ChatRosacea Today the world's first Global Rosacea Coalition, supported by the National Rosacea Society and many leading rosacea experts, called for greater ...
mehr
30.03.2015 – 14:54
Sunovion Pharmaceuticals Europe Ltd
Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA® ? (lurasidone) at the 23rd European Congress of Psychiatry
Vienna (ots/PRNewswire) - Sunovion Pharmaceuticals Europe Ltd. will present 10 new research posters on LATUDA(R) (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, at the 23rd European Congress of Psychiatry (EPA). The meeting will be held 28-31 March 2015 in Vienna, Austria. "We are ...
mehr
27.03.2015 – 14:03
Sanofi Pasteur MSD GmbH
GARDASIL® 9, New HPV Vaccine from Sanofi Pasteur MSD Granted Positive Opinion by European Committee for Medicinal Products for Human Use
Lyon, France (ots/PRNewswire) - European Committee for Medicinal Products for Human Use (CHMP) granted positive opinion for GARDASIL 9, the first 9-valent HPV vaccine Sanofi Pasteur MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted ...
mehr

24.03.2015 – 12:26
Astellas Pharma Europe Limited
Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress
London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...
mehr
19.03.2015 – 13:02
Astellas Pharma Europe Ltd. and Medivation, Inc.
New Enzalutamide Data to Be Presented in Late Breaking News Plenary Session at European Association of Urology Congress
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. and Medivation, Inc. announced that two enzalutamide abstracts will be presented at the annual European Association of Urology (EAU) Congress on March 24, 2015 in Madrid, Spain. (Logo: http://photos.prnewswire.com/prnh/20140522/689211 ) (Logo: ...
mehr
10.03.2015 – 10:04
DENTSPLY Implants
Treatment Solutions From DENTSPLY Implants for Improved Quality of Life
Cologne, Germany (ots/PRNewswire) - A prosthetic solution with the comfort of a fixed restoration; a patient-specific suprastructure on transgingival implants that eliminates the need for additional abutments; and an implant for sloped ridge situations for excellent esthetic results. (Logo: http://photos.prnewswire.com/prnh/20150310/732980-a ) (Logo: ...
mehr
10.03.2015 – 10:02
DENTSPLY Implants
DENTSPLY Implants-Continuous Commitment to Innovation, Science and Clinical Research
Cologne, Germany (ots/PRNewswire) - DENTSPLY Implants remains strongly committed to innovation, science and clinical research. Parallel to expanding worldwide, DENTSPLY Implants has continued its dedication to innovation, science and clinical research. The company is now truly global and the commitment to the extensive clinical research program and innovative product ...
mehr
05.03.2015 – 09:02
Sanofi Pasteur MSD GmbH
European Commission Grants "2+1 Immunization Schedule" for Hexyon® 6-in-1 Paediatric Vaccine
Lyon, France (ots/PRNewswire) - This decision opens the way to making Hexyon(R) available to more infantsin European countries Sanofi Pasteur MSD announced today that the European Commission has granted a new vaccination schedule of the 6-in-1 paediatric vaccine Hexyon(R) (DTaP-IPV-HB-Hib vaccine) for a "2+1" schedule of administration, in addition to other possible ...
mehr
24.02.2015 – 07:00
BioMed X GmbH
Roche and BioMed X collaborate to develop nanomaterial-based biosensors for near-patient testing
Heidelberg (ots) - Roche and BioMed X announced today that they have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene. Outstanding early career scientists from leading academic ...
mehr

23.02.2015 – 13:15
Holostem Terapie Avanzate - Centro di Medicina Rigenerativa "Stefano Ferrari" - Chiesi Farmaceutici S.p.A.
Europe Approves Holoclar®, the First Stem Cell-Based Medicinal Product
Parma And Modena, Italy (ots/PRNewswire) - The collaboration between a public excellent research center and a solid private pharmaceutical company allowed to achieve an extraordinary result, entirely "made in Italy": the first medicinal product containing stem cells approved in the Western world The European Commission has granted a conditional marketing authorization, ...
mehr
20.02.2015 – 11:31
Merck Healthcare
Merck Serono and Sysmex Inostics Announce First Liquid Biopsy RAS Biomarker Testing Center Opens: Important Milestone for mCRC Patients
Darmstadt, Germany And Barcelona, Spain (ots/PRNewswire) - - Vall d'Hebron, Spain: first hospital to use liquid biopsy RAS biomarker testing technology - Leading research center will use technology to evolve understanding of who will benefit most from targeted treatment to improve patient outcomes - Liquid biopsy ...
mehr
16.02.2015 – 18:14
Centre hospitalier Universitaire de Sherbrooke
Major Clinical Breakthrough at the Centre de recherche du CHUS in Sherbrooke, Quebec, Canada - A Clinical Study Demonstrates That Technetium Produced in a Cyclotron Is Equivalent to That Produced in a Nuclear Reactor
Sherbrooke, Quebec (ots/PRNewswire) - - Download photos and videos at http://cr.chus.qc.ca/cyclotron-crchus #cyclotronCRCHUS Researchers at the Centre de research du Centre hospitalier universitaire de Sherbrooke (CRCHUS) unveiled today the results of a clinical study demonstrating equivalency between ...
mehr
13.02.2015 – 09:36
Merck Healthcare Germany
CORRECTION - Merck: Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
Darmstadt, Germany (ots/PRNewswire) - In the news release, "Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan" issued on 13 Feb 2015 06:33 GMT, by Merck over PR Newswire, we are advised by a representative of the company that in the third paragraph ...
mehr
13.02.2015 – 07:36
Merck Healthcare Germany
Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
Darmstadt, Germany (ots/PRNewswire) - - Not intended for US- and UK-based media - Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science ...
mehr
31.01.2015 – 00:26
Shire Pharmaceuticals Group Plc
Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
Lexington, Massachusetts (ots/PRNewswire) - Shire plc announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to ...
mehr

21.01.2015 – 22:36
Shire Pharmaceuticals Group Plc
Shire Added to Global 100 Sustainability Index
Lexington, Massachusetts And Zug, Switzerland (ots/PRNewswire) - Shire plc announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd in the index, which is being revealed during the World Economic Forum in Davos this week. The Global 100 Index is a global ranking by Canada-based media and investment advisory company, Corporate Knights, of the top sustainability ...
mehr
19.01.2015 – 08:02
UC RUSAL
UC RUSAL Opens a Modern Epidemiology Centre in Guinea
Conakry, Guinea (ots/PRNewswire) - UC RUSAL , a leading global aluminium producer, announces that construction of the "Centre for epidemic and microbiological research and treatment" in the Kindia administrative region of the Republic of Guinea has completed. The Centre will support Guinea's national health system and help fight the spread of the Ebola virus. The opening ceremony which took place on 17 January was ...
mehr
16.01.2015 – 18:43
Astellas European Foundation
Shortlist Announced for Astellas European Foundation Transplantation Grant
Chertsey, England (ots/PRNewswire) - $150,000 Grant will be awarded on Saturday 24th January The Astellas European Foundation has announced the shortlist for the Transplantation Grant. The Grant programme supports basic medical and related scientific programmes which contribute to advancements in transplantation. The five finalists are from Denmark, Germany, The ...
mehr
13.01.2015 – 16:01
Debiopharm International SA
Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital
Lausanne, Switzerland (ots/PRNewswire) - GenePOC is a Canadian company which has developed a rapid, innovative, low cost MDx platform for the detection of infectious diseases Debiopharm Diagnostics [https://www.debiopharm.com/about-us/debiopharm-diagnostics-s-a.html ], part of Debiopharm Group [https://www.debiopharm.com/about-us/debiopharm-group.html ](TM), is proud ...
mehr
12.01.2015 – 08:32
Debiopharm International SA
Debiopharm Group(TM) Regains Full Rights to Alisporivir Program
Lausanne, Switzerland (ots/PRNewswire) - - Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement with Novartis to regain full rights to Alisporivir (DEB025) currently completing two Phase 2 studies of interferon-free treatment in ...
mehr
11.01.2015 – 17:04
Shire plc and NPS
PLShire to Acquire NPS Pharma as Further Step in Building a Leading Biotech
Dublin And Bedminster, New Jersey (ots/PRNewswire) - Transaction valued at $5.2 billion Enhances growth profile Shire plc and NPS Pharmaceuticals, Inc. today announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of ...
mehr

Vorherige41424344454647484950Nächste